-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Gusageu sepsis injection is the world's first monoclonal anti-human leukocyte interleukin-23 (IL-23) approved for psoriasis treatment, which destroys the iLE-23 medial conduction, activation and procastod reaction of cytokines by blocking psoriasis by blocking IL-23 binding to cell surface IL-23 receptors.
the approved Gussage Yu sing-in injection was declared by Janssen-Cilag International NV, agent of Xi'an Jansen-Cilag Pharmaceutical Co., Ltd., which was included in the list of the country's first batch of clinically urgently needed new drugs.
the State Drug Administration has accelerated the approval of the listing of the variety in accordance with the procedure sifted at the priority review and approval process.
So far, the State Drug Administration has approved 25 imports of drugs listed for clinically urgent overseas drugs.
Source: State Drug Administration.